Effects of mental illness and aging in two thalamic nuclei.
We previously reported a schizophrenia associated reduction of neuronal and oligodendrocyte number in the anterior principal thalamic nucleus (APN) in a cohort of severely impaired elderly subjects with schizophrenia (SZ) relative to age matched nonpsychiatric controls (NCs). The present study was undertaken to determine 1) if those findings could be replicated in an independent sample of less chronically impaired subjects with SZ and NCs stratified across a broader age range; 2) if the findings are specific to SZ or are also seen in unipolar major depressive (MDD) or bipolar disorder (BPD); and 3) if the findings are specific to the APN or also seen in another thalamic nucleus. Computer assisted stereological methods were employed to determine the number of neurons and oligodendrocytes in the APN and centromedian nucleus (CMN) of the Nissl-stained thalamic sections maintained by the Stanley Foundation Brain Bank. This collection includes specimens from NCs and age matched subjects with diagnoses of SZ, MDD, or BPD who died between the ages of 25 and 68. Data were analyzed by mixed-effects linear regressions adjusting for demographic variables and known history of exposure to psychotropic medications. Oligodendrocyte number was decreased in both nuclei relative to NCs in subjects with SZ and in that subset of subjects with BPD who had experienced psychotic episodes. Compared to NCs both of these patient groups also exhibited an attenuation of an age-related increase in the number of oligodendrocytes. Contrary to our previous report, we did not detect a SZ-associated deficit in neuronal number in the APN. A history of exposure to neuroleptics, however, was associated with a decrease in neuronal number in both nuclei, but this decrease did not vary in relation to cumulative lifetime neuroleptic exposure in fluphenazine equivalents. Among subjects with psychiatric diagnoses, exposure to lithium was associated with an increase in the number of oligodendrocytes. No effects were detected for exposure to anticonvulsants or for abuse of alcohol or other substances.
Byne
William
W
Division of Basic and Laboratory Research, Bronx Veterans Affairs Medical Center, Bronx, NY 10467, United States. william.byne@mssm.edu
Tatusov
Alex
A
Yiannoulos
Georgia
G
Vong
Ghe S
GS
Marcus
Sue
S
D000328:Adult; D000367:Age Factors; D000375:Aging / Q000473:pathology*; D020643:Anterior Thalamic Nuclei / Q000473:pathology; D014150:Antipsychotic Agents / Q000009:adverse effects; D001714:Bipolar Disorder / Q000473:pathology; D002452:Cell Count; D003865:Major Depressive Disorder / Q000473:pathology; D005260:Female; D005476:Fluphenazine / Q000009:adverse effects; D006801:Humans; D020646:Intralaminar Thalamic Nuclei / Q000187:drug effects / Q000473:pathology; D008297:Male; D001523:Mental Disorders / Q000175:diagnosis / Q000473:pathology*; D008875:Middle Aged; D009474:Neurons / Q000187:drug effects / Q000473:pathology; D009836:Oligodendroglia / Q000187:drug effects / Q000473:pathology; D012559:Schizophrenia / Q000473:pathology; D013787:Thalamic Nuclei / Q000187:drug effects / Q000473:pathology*
D014150:Antipsychotic Agents; D005476:Fluphenazine